Tetratherix Jumps on Debut, Capping Strong Week of ASX Listings

Tetratherix jumps on debut, capping strong week of ASX listings

The medical device manufacturer has developed a treatment for bone and tissue repair. Shares jumped 7 per cent when they hit the sharemarket on Monday morning.

Tetratherix Hits the ASX: What Investors Should Know

Tetratherix Limited (ASX: TTX) officially began trading on the Australian Securities Exchange following a successful initial public offering that raised A$25 million through the issuance of 8.68 million shares at A$2.88 each. The float places the company’s market capitalisation at approximately A$145 million. Importantly, the capital raised leaves Tetratherix with an estimated cash balance of…

Health Check: Tetratherix breaks biotech IPO drought with 13pc gain on debut

Tetratherix’s listed life starts on a solid note Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come Orthocell chalks up first commercial US procedure for its Remplir device Today’s ASX debut of wound management house Tetratherix (TTX) has raised the hopes of other life-science plays that have eyed an IPO but have relegated the idea to the too-hard basket. Having downsized its offer from $35 million $25 million to banis…